2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspring (US FDA approval for thyroid eye disease).”
2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspring (US FDA approval … 続きを読む
CHUGAI PHARMACEUTICAL CO.,LTD.
2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the 2026 Porter Prize.”
2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the 2026 Porter Prize.”
2026-10-13 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding bamiquibalt (1-year data in macular edema associated with non-infectious uveitis).”
2026-10-13 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding bamiquibalt (1-year data i … 続きを読む
2026-09-30 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the establishment of a subsidiary in South Korea.”
2026-09-30 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the establishment of a subsidiary in S … 続きを読む
2026-09-29 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical and InxMed have entered into a worldwide licensing agreement regarding the RAF-MEK molecular adhesive SPYK04.”
2026-09-29 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical and InxMed have entered into a worldwid … 続きを読む
2026-09-28 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the discontinuation of obesity treatment development for GYM329 (emugrobart), the return of licenses, and the resumption of SMA development.”
2026-09-28 CHUGAI PHARMACEUTICAL CO.,LTD. “Announcement regarding the discontinuation of obesity treatme … 続きを読む
2026-09-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding cefaxelcene sodium (interim analysis results from the Phase III IMAGINATION trial).”
2026-09-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding cefaxelcene sodium (interi … 続きを読む
2026-09-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for lorlatinib in ALK fusion gene-positive non-small cell lung cancer.”
2026-09-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved a … 続きを読む
2026-09-17 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Lunsmio (data from the international collaborative Phase III CELESTIMO trial for relapsed or refractory follicular lymphoma).”
2026-09-17 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Lunsmio (data from the int … 続きを読む
2026-09-16 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for tovorafenib in gliomas positive for BRAF V600 mutations and BRAF fusion genes.”
2026-09-16 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved a … 続きを読む